Fostamatinib disodium hexahydrate

Cat. No.: HY-13038B

CAS No.: 914295-16-2

Molecular Formula: $C_{23}H_{36}FN_6Na_2O_{15}P$

Molecular Weight: 732.51

Target: Syk; FLT3

Pathway: Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 31.81 mg/mL (43.43 mM; Need ultrasonic)

H_2O : 2 mg/mL (2.73 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.3652 mL	6.8258 mL	13.6517 mL
5 mM	0.2730 mL	1.3652 mL	2.7303 mL
10 mM	0.1365 mL	0.6826 mL	1.3652 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Fostamatinib (R788) disodium hexahydrate is the oral prodrug of the active compound R406[1]. R406 is an orally available and competitive Syk/FLT3 inhibitor with a K_i of 30 nM and an IC_{50} of 41 nM[2]. R406 also inhibits Lyn (IC_{50}=63 nM) and Lck (IC_{50}=37 nM)[3].

IC_{50} & Target

Syk, FLT3[2]

In Vivo

Fostamatinib (R788) is highly bioavailable, and rapidly absorbed in Louvain rats. R406 following a single oral dose of R788 10 mg/kg or 20 mg/kg: $AUC_{0\text{-}16\ hrs}$= 10618 ng*h/mL and 30650 ng*h/mL respectively; C_{max}=2600 ng/mL and 6500 ng/mL respectively (observed at 1 hour); $t_{1/2}$=4.2 hours. The prodrug was not detected in plasma suggesting R788 is completely converted to R406[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Med. 2018 Feb;24(2):232-238.
- Cancer Cell. 2014 Feb 10;25(2):226-42.
- Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.
- Blood Cancer J. 2014 Aug 22;4(8):e240.
- Oxid Med Cell Longev. 2021 Feb 26.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Stephen P McAdoo, et al. Fostamatinib Disodium. Drugs Future. 2011;36(4):273.

[2]. Sylvia Braselmann, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008.

[3]. Hoon-Suk Cha , et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther. 2006 May;317(2):571-8.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA